CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Aptar Q3 profit falls on Russia deconsolidation charge

By Reuters News


Overview

  • Drug delivery and dispensing firm's Q3 sales rose 6%, beating analyst expectations

  • Adjusted EPS for Q3 was $1.52, beating analyst expectations

  • Reported EPS fell to $0.51 due to Russian subsidiary deconsolidation


Outlook

  • Aptar sees Q4 2026 adj EPS between $1.39 and $1.47

  • Company expects full-year results supported by Pharma growth, especially in consumer healthcare and injectables

  • Closures segment expected to see increased demand, driven by beverage technology innovation


Result Drivers

  • RUSSIAN DECONSOLIDATION - A government decree drove a $60.4 mln after-tax charge, cutting reported EPS by $0.94

  • PHARMA SEGMENT - Co said growth in central nervous system, pulmonary, injectables and consumer healthcare therapies drove Pharma segment sales

  • BEAUTY DEMAND - Increased demand for prestige fragrance dispensing, color cosmetics and hair care applications boosted Beauty segment sales

  • CLOSURES INNOVATION - Strong demand for beverage dispensing closures, bottled water, concentrates and condiments drove Closures segment growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$1.02 bln

$984.44 mln (7 Analysts)

Q3 Adjusted EPS

Beat

$1.52

$1.47 (8 Analysts)

Q3 EPS

$0.51

Q3 Net Income

$33 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

  • Wall Street's median 12-month price target for AptarGroup, Inc. is $154.78, about 18.5% above its October 29 closing price of $130.64

  • The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook

  • Oct 29 - Ligand Pharmaceuticals Q3 royalty revenue jumps 51%

  • Oct 29 - Phathom Pharmaceuticals Q3 revenue rises 71%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.